Rapid amelioration of hyperglycemia facilitated by dasatinib in a chronic myeloid leukemia patient with type 2 diabetes mellitus

Internal Medicine

Volumn 51, Issue 19, 2012, Pages 2763-2766

  Ono, Keiko ^a,b   Suzushima, Hitoshi ^a   Watanabe, Yuko ^a   Kikukawa, Yoshitaka ^a   Shimomura, Taizou ^a   Furukawa, Noboru ^b   Kawaguchi, Tatsuya ^c   Araki, Eiichi ^b  

^a Kumamoto Shinto General Hospital (formerly NTT West Kyushu Hospital)   (Japan)

^b KUMAMOTO UNIVERSITY   (Japan)

^c KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

Author keywords

Chronic myeloid leukemia; Insulin secretion; Insulin sensitivity; Type 2 diabetes mellitus; Tyrosine kinase inhibitors

Indexed keywords

C PEPTIDE; DASATINIB; DEFERASIROX; GLIMEPIRIDE; GLYCOSYLATED ALBUMIN; HEMOGLOBIN A1C; INSULIN ASPART; INSULIN DETEMIR;

ADULT; ANEMIA; ARTICLE; BASOPHIL; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DRUG TOLERANCE; FERRITIN BLOOD LEVEL; GLUCOSE BLOOD LEVEL; HEMOCHROMATOSIS; HOSPITALIZATION; HUMAN; HYPERFERRITINEMIA; HYPERGLYCEMIA; LEUKOCYTOSIS; LOW DRUG DOSE; MALAISE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; THIRST; THROMBOCYTOPENIA;

ANTINEOPLASTIC AGENTS; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DRUG RESISTANCE, NEOPLASM; HUMANS; HYPERGLYCEMIA; HYPOGLYCEMIC AGENTS; INSULIN; LEUKEMIA, MYELOID, ACCELERATED PHASE; MALE; MIDDLE AGED; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 84867800328     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.51.8314     Document Type: Article

References (14)

1. Breccia M, Muscaritoli M, Aversa Z, Mandelli F, Alimena G. Imatinib mesylate may improve fasting blood glucose in diabetic Ph+ chronic myelogenous leukemia patients responsive to treat-ment. J Clin Oncol 156: 4653-4655, 2004.
2. Veneri D, Franchini M, Bonora E. Imatinib and regression of type 2 diabetes. New Engl J Med 352: 1049-1050, 2005.
3. Breccia M, Muscaritoli M, Cannella L, Stefanizzi C, Frustaci A, Alimena G. Fasting glucose improvement under dasatinib treat-ment in an accelerated-phase chronic myeloid leukemia patient unresponsive to imatinib and nilotinib. Leuk Res 32: 1626-1628, 2008.
4. Agostino NM, Chinchilli VM, Lynch CJ, et al. Effect of tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels indiabetic and nondiabetic patients in general clinical practice. J Oncol Pharm Pract 17: 197-202, 2011.
5. Breccia M, Muscaritoli M, Gentilini F, et al. Impaired fasting glu-cose level as metabolic side effect of nilotinib in non-diabetic chronic myeloid leukemia patients resistant to imatinib. Leuk Res 31: 1770-1772, 2007.
6. Kashiwagi A, Kasuga M, Araki E, et al. Committee on the Stan-dardization of Diabetes Mellitus-Related Laboratory Testing of Ja-pan Diabetes Society. International clinical harmonization of gly-cated hemoglobin in Japan: From Japan Diabetes Society to Na-tional Glycohemoglobin Standardization Program values. J Diabe-tes Invest 3: 39-40, 2012.
7. Bohm S, Hess D, Gillessen S, Brandle M. Improved glycemic control with the multi-receptor tyrosine kinase inhibitor pazopanib. Diab Care 33: e82, 2010.
8. Hagerkvist R, Sandler S, Mokhtari D, Welsh N. Amelioaration of diabetes by imatinib mesylate (Gleevec®): role of β-cell NF-κB activation and anti-apoptotic preconditioning. FASEB J 21: 618-628, 2007.
9. Louvet C, Szot GL, Lang J, et al. Tyrosine kinase inhibitors re-verse type 1 diabetes in nonobese diabetic mice. PNAS 105: 18895-18900, 2008.
10. Hagerkvist R, Jansson L, Welsh N. Imatinib mesylate improves in-sulin sensitivity and glucose disposal rates in rats fed a high-fat diet. Clin Sci 114: 65-71, 2008.
11. Wolf AM, Wolf D, Rumpold H, et al. The kinase inhibitor imatinib mesylate inhibits TNF-α production in vitro and prevents TNF-dependent acute hepatic inflammation. PNAS 102: 13622-13627, 2005.
12. Han MS, Chung KW, Cheon HG, et al. Imatinib mesylate reduces endoplasmic reticulum stress and induces remission of diabetes in db/db mice. Diabetes 58: 329-336, 2009.
13. 2+-dependent insulin release. Am J Physiol End-crinol Metab 292: E845-E852, 2007.
14. Kominato R, Fujimoto S, Mukai E, et al. Src activation generates reactive oxygen species and impairs metabolism-secretion cou-pling in diabetic Goto-Kakizaki and ouabain-treated rat pancreatic islets. Diabetologia 51: 1226-1235, 2008.